Gainesville, Florida 32610


The purpose of this study is to see if there are any differences between patients who receive Levetiracetam extended-release tablets for one week after surgery to remove a brain tumor versus those who receive Levetiracetam extended-release tablets for six weeks after surgery. Specifically, we will see if one group has less side effects than the other, and whether or not one group has more seizures than the other.

Study summary:

Because seizures are one of the leading neurologic complications in brain tumor patients, neurosurgeons prescribe antiepileptic drugs (AEDs) to help prevent them. Although the American Academy of Neurology (AAN) guidelines recommend that AEDs be stopped after the first post-operative week in patients without seizures, there is no standard length of treatment and some patients may stay on AEDs indefinitely. In an attempt to develop clinical guidelines for AED use in post-operative brain tumor patients, we will try to determine if taking levetiracetam extended-release (Keppra XR) for 1 week results in less neurotoxicity than taking it for 6 weeks.


Inclusion Criteria: - Adult (>18 years of age and older) patients who have or will have undergone surgical resection or biopsy of a supratentorial brain tumor and are able to consent for themselves. - Able to be randomized prior to or up to 48 hours after surgery. Exclusion Criteria: - No known history of seizure activity. - Pregnant or breastfeeding. - Renal dysfunction (CrCl < 30ml/min). - Beck's Depression Inventory (BDI) ≥14 - Allergy to levetiracetam.



Primary Contact:

Principal Investigator
Maryam Rahman, MS, MD
University of Florida

Jessica Smith, RN
Phone: (352) 273-7773

Backup Contact:


Location Contact:

Gainesville, Florida 32610
United States

Jessica Smith, RN
Phone: 352-273-7773

Site Status: Recruiting

Data Source:

Date Processed: October 18, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.